Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer
Authors:
- 13 January 2013
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 71 (4) , 843-851
Abstract
Ethnic diversity of genetic polymorphism can result in individual differences in the efficacy and toxicity of cancer chemotherapy. We analyzed 20 germline polymorphisms in 10 genes (TS, MTHFR, ERCC1, XPD, XRCC1, ABCC2, AGXT, GSTP1, GSTT1 and GSTM1) from prospectively enrolled 292 Korean patients treated with adjuvant oxaliplatin plus leucovorin plus 5-fluorouracil (FOLFOX) for colon cancer. In contrast to previous studies in Caucasians, neutropenia (grade 3–4, 60.5 %) was frequently observed, whereas only 16.4 % experienced grade 2 or more sensory neuropathy. Neutropenia was more frequent in MTHFR 677TT [adjusted odds ratio (OR) 2.32, 95 % confidence interval (CI) 1.19–4.55] and ERCC1 19007TT (adjusted OR 4.58, 95 % CI 1.20–17.40) genotypes. Patients harboring XRCC1 23885GG experienced less grade 2–4 neuropathy [adjusted OR 0.52, 95 % CI 0.27–0.99]. MTHFR 677TT (p = 0.002) and XRCC1 23885GG (p = 0.146) genotypes were also more prevalent in Koreans compared to Caucasians. TS ‘low’ genotype (adjusted HR 1.83, 95 % CI 1.003–3.34) was significantly related to shorter disease-free survival. Overall survival was not significantly different according to the polymorphisms. Polymorphisms in MTHFR, XRCC1 and TS are related to toxicities and disease-free survival in patients with colon cancer. The ethnic differences in frequencies of genotypes may explain the ethnic difference in toxicity profile following adjuvant FOLFOX chemotherapy.Keywords
This publication has 28 references indexed in Scilit:
- Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05Journal of Clinical Oncology, 2010
- Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancerBritish Journal of Cancer, 2009
- Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon CancerJournal of Clinical Oncology, 2009
- Pharmacogenetics in Colorectal Cancer: a Systematic ReviewPharmacogenomics, 2008
- Pharmacogenomics of Drug-Metabolizing Enzymes and Drug Transporters in Chemotherapy2008
- Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal CancerJournal of Clinical Oncology, 2007
- Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracilInternational Journal of Oncology, 2006
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerNew England Journal of Medicine, 2004
- Pharmacogenomics — Drug Disposition, Drug Targets, and Side EffectsNew England Journal of Medicine, 2003
- Thymidylate Synthase Expression in Colorectal Cancer: A Prognostic and Predictive Marker of Benefit From Adjuvant Fluorouracil-Based ChemotherapyJournal of Clinical Oncology, 2002